Single-center experience suggests cfDNA NGS can aid in diagnosing infections in critically ill children, indicating potential benefits despite limitations.
Detection of pathogenic cfDNA through NGS from blood shows promising results as an additional diagnostic tool in critically ill pediatric patients with suspected infections. Clinical utility is currently still limited by its high cost, undetermined diagnostic validity and limitations in testing for resistances and restricted availability of raw sequencing data due to data-protection constraints.
No takes yet. Share an insight, caveat, or question.
Adolph et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: